1. Home
  2. BILL vs ATAI Comparison

BILL vs ATAI Comparison

Compare BILL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$47.44

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo ATAI Life Sciences N.V.

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$7.43

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
ATAI
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
BILL
ATAI
Price
$47.44
$7.43
Analyst Decision
Buy
Strong Buy
Analyst Count
21
8
Target Price
$57.90
$15.88
AVG Volume (30 Days)
2.6M
8.6M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,653,160,000.00
$4,089,000.00
Revenue This Year
$14.18
N/A
Revenue Next Year
$13.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.03
1227.60
52 Week Low
$31.41
$3.27
52 Week High
$57.21
$7.45

Technical Indicators

Market Signals
Indicator
BILL
ATAI
Relative Strength Index (RSI) 56.40 72.67
Support Level $46.72 $3.89
Resistance Level $49.60 N/A
Average True Range (ATR) 1.97 0.05
MACD -0.44 -0.07
Stochastic Oscillator 29.69 68.52

Price Performance

Historical Comparison
BILL
ATAI

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: